Cargando…

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

BACKGROUND: Direct-acting antiviral (DAA) agents target HCV proteins; some of these have already been approved for the treatment of HCV infection, while others are in development. However, selection of DAA-resistant viral variants may hamper treatment. The aim of this study was to illustrate potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paolucci, Stefania, Fiorina, Loretta, Mariani, Bianca, Gulminetti, Roberto, Novati, Stefano, Barbarini, Giorgio, Bruno, Raffaele, Baldanti, Fausto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878512/ https://www.ncbi.nlm.nih.gov/pubmed/24341898 http://dx.doi.org/10.1186/1743-422X-10-355

Ejemplares similares

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
por: Paolucci, Stefania, et al.
Publicado: (2020)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes
por: Costa, Vanessa D., et al.
Publicado: (2019)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

A41 Characterization of NS5 coding region resistance associated substitutions from DAA-naïve GT1 HCV-infected patients in a Portuguese cohort
por: Brandao, R, et al.
Publicado: (2018)

Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors
por: Kaushik-Basu, Neerja, et al.
Publicado: (2008)

Update on different aspects of HCV variability: focus on NS5B polymerase
por: Marascio, Nadia, et al.
Publicado: (2014)

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
por: Nutt, Jamie, et al.
Publicado: (2017)

Classification of HCV NS5B Polymerase Inhibitors Using Support Vector Machine
por: Wang, Maolin, et al.
Publicado: (2012)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2012)

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking
por: Karpiński, Tomasz M., et al.
Publicado: (2023)

Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents
por: Bartolini, Barbara, et al.
Publicado: (2017)

Correction: Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2013)

EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
por: Paolucci, Stefania, et al.
Publicado: (2021)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Zika virus NS3 is a canonical RNA helicase stimulated by NS5 RNA polymerase
por: Xu, Shan, et al.
Publicado: (2019)

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
por: Piralla, Antonio, et al.
Publicado: (2011)

Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches
por: Ikram, Aqsa, et al.
Publicado: (2018)

Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection
por: Sillanpää, Maarit, et al.
Publicado: (2009)

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia
por: Aissa Larousse, Jameleddine, et al.
Publicado: (2015)

Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver
por: Zhang, Jin, et al.
Publicado: (2019)

Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide
por: Wu, Ruihong, et al.
Publicado: (2019)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Exploring the inhibitory potential of Nigella sativa against dengue virus NS2B/NS3 protease and NS5 polymerase using computational approaches
por: Mukhtar, Mamuna, et al.
Publicado: (2023)

Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection
por: Rahimi, Pooneh, et al.
Publicado: (2021)

A Cell-Based Assay for RNA Synthesis by the HCV Polymerase Reveals New Insights on Mechanism of Polymerase Inhibitors and Modulation by NS5A
por: Ranjith-Kumar, C. T., et al.
Publicado: (2011)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

The Interface between Methyltransferase and Polymerase of NS5 Is Essential for Flavivirus Replication
por: Li, Xiao-Dan, et al.
Publicado: (2014)

The flavivirus polymerase NS5 regulates translation of viral genomic RNA
por: Fajardo, Teodoro, et al.
Publicado: (2020)

First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Hasanshahi, Zahra, et al.
Publicado: (2021)

The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
por: Hebner, Christy M., et al.
Publicado: (2012)

Cell Penetrable Humanized-VH/V(H)H That Inhibit RNA Dependent RNA Polymerase (NS5B) of HCV
por: Thueng-in, Kanyarat, et al.
Publicado: (2012)

QSAR study of HCV NS5B polymerase inhibitors using the genetic algorithm-multiple linear regression (GA-MLR)
por: Rafiei, Hamid, et al.
Publicado: (2016)

Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation
por: Han, Di, et al.
Publicado: (2021)

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis
por: Santos, Ana Paula de Torres, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rpcfvnuu40jdinnv5hahe7pps7